Svenska

Västra Hamnen: Heliospectra - Pandemic taking its toll

Report this content

Västra Hamnen Corporate Finance has released a research update on Heliospectra AB following the company's report for Q2 2020. The pandemic has caused among the lowest sales and order figures for years and another capital injection might be unavoidable. We lower our valuation interval to SEK 5.00 - 7.50 per share, writes Västra Hamnen.
 

  • Both sales and order intake are hit hard by the pandemic
  • We anticipate another capital injection in Q1 or sooner
  • We lower our valuation interval to SEK 5.00 – 7.50 per share

Last Friday, Heliospectra presented its Q2 report and it stands clear that the company is hit hard from the ongoing pandemic. The company’s two huge orders that were announced in Q4 are still pending and both the sales and order intake are markedly subdued. The company is taking measures to bring down operational costs, but we think the company will face tough times in the near future, not least with regards to the capital situation. We therefore lower our valuation interval to SEK 5.00 – 7.50 per share.

The full report is available here.

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se

Prenumerera